Hoth Therapeutics Relocates Executive Offices

TL;DR

HOTH moved its HQ to NYC, effective 6/14.

AI Summary

Hoth Therapeutics, Inc. filed an 8-K on June 17, 2024, reporting a change in its principal executive offices to 590 Madison Avenue, 21st Floor, New York, NY 10022, effective June 14, 2024. The company also updated its telephone number to (646) 756-2997.

Why It Matters

A change in principal executive offices can indicate operational shifts or strategic realignments for the company.

Risk Assessment

Risk Level: low — This filing primarily concerns administrative changes related to the company's office location and contact information, with no immediate financial or operational risks disclosed.

Key Players & Entities

• Hoth Therapeutics, Inc. (company) — Registrant
• 590 Madison Avenue, 21st Floor, New York, NY 10022 (location) — New Principal Executive Offices
• (646) 756-2997 (phone_number) — New Business Phone Number
• June 14, 2024 (date) — Effective date of office change
• June 17, 2024 (date) — Filing date

FAQ

From the Filing

0001213900-24-053359.txt : 20240617 0001213900-24-053359.hdr.sgml : 20240617 20240617164110 ACCESSION NUMBER: 0001213900-24-053359 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240614 ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240617 DATE AS OF CHANGE: 20240617 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Hoth Therapeutics, Inc. CENTRAL INDEX KEY: 0001711786 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 821553794 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38803 FILM NUMBER: 241048876 BUSINESS ADDRESS: STREET 1: 590 MADISON AVENUE STREET 2: 21ST FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: (646)756-2997 MAIL ADDRESS: STREET 1: 590 MADISON AVENUE STREET 2: 21ST FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 8-K 1 ea0207966-8k_hoththera.htm CURRENT REPORT false --12-31 0001711786 0001711786 2024-06-14 2024-06-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM  8-K   CURRENT REPORT   Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported)  June 14, 2024   Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter)   Nevada   001-38803   82-1553794 (State or other jurisdiction of incorporation)   (Commission File Number)   (I. R. S. Employer Identification No.)   590 Madison Ave., 21 st Floor New York ,  New York   10022 (Address of principal executive offices, including ZIP code)   ( 646 )  756-2997 (Registrant’s telephone number, including area code)   Not Applicable (Former name or former address, if changed since last report)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)     ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)     ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common stock, $0.0001 par value   HOTH   The  Nasdaq  Stock Market LLC   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company  ☒   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐           Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.   On June 14, 2024, the board of directors (the “Board”) of Hoth Therapeutics, Inc. (the “Company”) approved an amendment (the “Amendment”) to the Company’s Amended and Restated Bylaws, as amended (the “Bylaws”).   The Amendment amends and rest